Product Description
BCP-01 is an anti-SARS-CoV-2 antibody cocktail made up of IMM20184, IMM20190 and IMM20253 antibodies. (Sourced from: https://www.science.org/doi/10.1126/sciimmunol.abl9943)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Immunome
Company Location: EXTON PA 19341
Company CEO: Purnanand D. Sarma
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IMM-BCP-1001 | P1 |
Terminated |
COVID-19 |
2023-01-06 |